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The role of the feline immunodeficiency virus (FIV) vif gene in establishing productive infection in feline peripheral blood
mononuclear cells (PBMCs) and monocyte-derived macrophages (MDMs) was examined in cell culture systems. A 375-bp
deletion was introduced into the vif gene of the wild-type FIV-pPPR infectious molecular clone to produce Vif deletion mutant
FIV-pPPRDvif. This mutant FIV proviral construct expressed FIV proteins p24gag and gp100env in transfected Crandell feline
kidney cells as measured by immunoprecipitation and Western blot analysis as well as immunocytochemical analysis; these
cultures produced very low levels of virus by cocultivation of transfected cells with PBMCs and K-258 cells, as measured by
production of p24gag. Replication kinetics of wild-type and vif-deleted virus were compared in PBMCs and monocyte-derived
macrophages (MDMs) by infection with cell-free virus preparations. Similar to findings with other lentiviruses, the vif gene
was found to be essential for establishment of productive FIV infection in both PBMCs and MDMs. This study indicates that
vif is essential for productive FIV infection of host target cells in vitro and that FIV-pPPRDvif may be an excellent candidate
viral mutant for attenuated virus vaccine studies. © 1999 Academic Press
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Feline immunodeficiency virus (FIV) is a retrovirus of
he lentivirus subfamily that causes an immune defi-
iency syndrome in domestic cats similar in clinical
ourse and pathological features to that observed with
cquired immune deficiency syndrome (AIDS) in humans
nfected with the human immunodeficiency virus type I
HIV-1) (Barlough et al., 1991; Pedersen et al., 1987; Sie-
elink et al., 1990). The genome of FIV is closely related
o other lentiviruses and encodes the structural and
nzymatic genes, gag, pol, and env. In addition, FIV also
ncodes for three accessory genes: rev, orf A, and vif. All
nown lentiviruses encode a vif gene, except equine
nfectious anemia virus (EIAV) and Vif sequences are
ighly conserved among different isolates of the same
irus, suggesting that the vif gene may be important for
atural infection. The HIV-1 Vif protein has been found to
nhance virus infectivity in producer cells, most likely by
odulating virus assembly and/or budding (Fouchier et
l., 1996). Deletion of vif restricts virus replication in
arget cells at a postentry step leading to reduced re-
erse transcription of viral RNA (Goncalves et al., 1996;
ova and Volsky, 1993; von Schwedler et al., 1993), either
irectly by affecting reverse transcription or indirectly
uring uncoating or disassembly of the virion core. Im-
ortantly, Vif has been shown to be required for efficient
1 To whom reprint requests should be addressed. Fax: (530) 752-
u414. E-mail: eesparger@ucdavis.edu.
25IV-1 replication in vitro in peripheral blood mononuclear
ells (PBMCs) and macrophages, primary targets of
IV-1 infection in vivo (Chowdhury et al., 1996; Fan and
eden, 1992; Gabuzda et al., 1994; Kawamura et al.,
994).
The FIV vif gene is similar in size and genomic location
o that of HIV-1-encoded vif (Tomonaga et al., 1992).
revious studies have shown that FIV vif is required for
ell-free infection of feline PBMCs and feline cell lines
uch as Crandell feline kidney (CrFK), G355–5, and
YA-1 (Shacklett and Luciw, 1994; Tomonaga et al.,
992). However, FIV vif-mutants can productively infect
YA-1 cells when cocultivated with CrFK cells trans-
ected with FIVDvif DNA, suggesting that cell-to-cell
ransmission is not affected by the deletion of the vif
ene (Tomonaga et al., 1992). Moreover, the FIV vif gene
s required for efficient viral replication in vivo during the
arly stage of infection in cats (Inoshima et al., 1996).
noshima et al. (1996) reported that inoculation of cats
ith FIVDvif-infected cells resulted in very low viral
oads. Nevertheless, the Dvif virus was able to replicate
n the lymph nodes, presumably by cell-to-cell transmis-
ion. In vivo cellular targets of FIV include CD41 and
D81 T cells, B cells, and macrophages (Beebe et al.,
994; Dean et al., 1996, 1999; English et al., 1993). Early
n primary FIV infection, there is a shift from T cells to
acrophages as the predominant cellular target, a find-
ng that may be crucial in the pathogenesis of FIV infec-
ion (Beebe et al., 1994). It is, therefore, important to
nderstand the role of FIV vif for virus replication in both
0042-6822/99 $30.00
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26 LOCKRIDGE ET AL.BMCs and macrophages. This report describes a vif-
utant of the WT FIV-pPPR clone and examines the role
f vif in establishment of cell-free infection in both feline
BMCs and macrophages, as well as in K-258 cells, an
nterleukin (IL)-2-dependent feline lymphoid cell line.
RESULTS AND DISCUSSION
The FIV-pPPRDvif molecular clone was derived from
he infectious molecular clone WT FIV-pPPR and en-
odes for a 375-bp deletion (bases 5530–5330) within the
if gene (Fig. 1); presence of the deletion was confirmed
y dideoxynucleotide sequencing. To verify expression
f structural viral proteins, immunoprecipitation and im-
unocytochemistry were used to assess expression of
IV p24gag and FIV surface glycoprotein gp100env in
rFK cells transfected with FIV-pPPRDvif plasmid DNA.
lthough nonpermissive for wild-type (WT) FIV-PPR rep-
ication, CrFK cells were chosen for these experiments
ecause they have been found permissive for WT FIV-
PPR protein expression and because optimal transfec-
ion protocols have been established for these cells.
mmunoprecipitation of viral proteins from CrFK cultures
ransfected with either WT FIV-pPPR or FIV-pPPRDvif
ollowed by Western blot analysis revealed comparable
roduction of p24gag by 48 h post-transfection (Fig. 2).
mmunocytochemical staining of CrFK cultures trans-
ected with FIV-pPPRDvif revealed expression of
p100env similar to that WT FIV-pPPR by 24–48 h post-
ransfection (Fig. 3). These observations indicated that
xpression of sequences downstream of the vif mutation
i.e., rev and env genes), as well as expression of struc-
ural proteins such as p24gag, was not affected during
onstruction of the proviral mutant.
To confirm that the FIV-pPPRDvif proviral DNA con-
truct produces replication-competent virus, transfected
rFK cells were cocultivated with PBMCs or K-258 cells,
FIG. 1. Construction of FIV-pPPRDvif. A 375-bp deletion (bp 5330–
704) was created within the vif gene of the FIV-pPPR molecular clone
y digestion with restriction enzymes SauI and HindIII followed by
eneration of blunt ends using the Klenow fragment of DNA polymer-cse I. The resulting clone is designated FIV-FIV-pPPRDvif.n IL-2-dependent feline lymphoid cell line, and virus
roduction by WT and vif-mutant virus were compared. In
ll PBMC cocultivation experiments, p24gag production
as consistently observed with the WT FIV-pPPR con-
truct but not in PBMCs cocultivated with mock-trans-
ected CrFK cells (Figs. 4A and 4B). However, viral rep-
ication for the FIV-pPPRDvif construct varied from se-
erely restricted (Fig. 4A) to completely restricted (Fig.
B) compared with WT in six independent experiments.
eplication of Vif-mutant virus was also seen in human
BMCs cocultivated with HeLa cells transfected with
IV-1 Vif mutants (Fan and Peden, 1992).
When K-258 cells were cocultivated with transfected
rFK cells, p24gag production was consistently ob-
erved with both WT FIV-pPPR and FIV-pPPRDvif con-
tructs (Fig. 4C); however, the replication of the FIV-
PPRDvif was severely attenuated compared with WT.
o p24gag was detected in K-258 cultures cocultivated
ith mock-transfected CrFK cells. Five repetitions of this
xperiment yielded consistent results that were similar
o what has been found with CrFK transfection and
ocultivation with MYA-1 cells (Tomonaga et al., 1992).
hese observations indicate that transfection of CrFK
FIG. 2. Expression of FIV p24gag after transfection of CrFK cells with
IV-pPPRDvif. CrFK cells (1 3 107) were electroporated with 30 mg of
ither WT FIV-pPPR (lane 3) or FIV-FIV-pPPRDvif (lane 4). At 48 h after
ransfection, immunoprecipitations were performed on cellular extracts
sing FIV-infected cat sera, and the proteins were electrophoretically
eparated on 12% SDS–polyacrylamide gels as previously described
Sawai et al., 1996). Immunoblot analysis was performed as described
reviously (Sawai et al., 1996). Uninfected CrFK cells (107 cells) (lane 1)
nd FL4 cells (107 cells) chronically infected with Petaluman FIV (lane
) were used as negative and positive controls, respectively. The
osition of p24gag is indicated by an arrow on the right, and the
olecular weight markers are indicated on the left.ells with the FIV-pPPRDvif proviral construct can pro-
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27FIV vif GENEuce virus capable of cell-to-cell transmission in both
BMCs and K-258 cells.
To determine whether the FIV vif gene was required for
nfection of PBMCs, WT and mutant virus stocks were
repared and used to evaluate cell-free virus infectivity.
ecause the FIV-pPPRDvif virus preparation was pre-
icted to exhibit low infectivity, infection studies were
onducted using equal concentrations of virion-associ-
ted p24gag. Production of FIV p24gag was observed in
BMCs infected with WT FIV-pPPR virus by 10 days
ostinfection (p.i.), and replication of virus increased over
ime (Fig. 5). However, productive infection was not ob-
erved from PBMCs inoculated with FIV-pPPRDvif
hroughout the time course of this study, as evidenced by
ack of detection of FIV p24gag in cell culture superna-
ants. These results are representative of those obtained
n three independent experiments. Thus, cell-free infec-
ivity of FIV-pPPRDvif is markedly reduced in feline PB-
Cs compared with WT FIV-pPPR.
To characterize FIV-pPPRDvif replication in feline mac-
ophages, MDM preparations were infected with equal
oncentrations of either WT FIV-pPPR or FIV-pPPRDvif,
ased on quantification of virion-associated p24gag. FIV
24gag production was observed in WT FIV-pPPR-in-
FIG. 3. Expression of FIV gp100 after transfection of CrFK cells with
IV-pPPRDvif. CrFK cells (1 3 105) transfected with either WT FIV-pPPR
r FIV-pPPRDvif were seeded onto Thermanox tissue culture slides
Nunc Inc.) from 24 to 48 h post-transfection and assessed for FIV
p100env expression (red stain) by an immunocytochemical assay
escribed in the text. Uninfected CrFK cells (A), cells 48 h post-
ransfection with WT FIV-pPPR (B), cells 24 h post-transfection with
IV-pPPRDvif (C), and cells 48 h post-transfection with FIV-pPPRDvif (D)cre presented above. Magnification, 1203.ected MDMs by day 3 p.i. (Fig. 6) and increased through-
ut the experiment. However, culture supernatants har-
ested from FIV-pPPRDvif-infected MDMs remained neg-
tive for viral antigen for the duration of the experiment.
n addition, FIV p24gag was not detected in uninfected
DM cultures. These results indicate that Vif is required
or cell-free virus infectivity in feline MDMs as well as in
eline PBMCs.
In this report, we cloned an FIV vif deletion mutant and
haracterized its replication properties in feline PBMCs
nd MDMs in cell culture systems. The FIV-pPPRDvif
FIG. 4. Replication kinetics of FIV-pPPRDvif after transfection of CrFK
ells and cocultivation with PBMCs or K-258 cells. CrFK cells were
ransfected with 10 mg of plasmid DNA and cocultivated with PBMCs (A
nd B) or K-258 cells (C) 24 h later. Virus production was measured in
ell culture supernatants every 3–5 days using a p24gag antigen
LISA.lone expressed viral proteins p24gag and gp100env
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28 LOCKRIDGE ET AL.nd produced virus capable of cell-to-cell transmission
n transfection of CrFK cells and cocultivation with
BMCs or K-258 cells, an IL-2-dependent feline lymphoid
ell line. However, when cell-free virus preparations
ere used for infection studies with feline PBMCs and
DMs, FIV-pPPRDvif virus was incapable of productive
nfection. These results indicate that FIV-pPPRDvif exhib-
ts a severely attenuated infectivity in both feline PBMCs
nd macrophages, host target cells of FIV infection in
ivo. Considering that molecular clone WT FIV-pPPR es-
ablishes productive FIV infection in experimentally in-
ected cats (Phillips et al., 1996, 1990; Sparger et al.,
994), FIV-pPPRDvif provides a valuable reagent for char-
cterizing vif as a determinant for virus replication in vivo.
n addition, inoculation of cats with FIV-pPPRDvif also
rovides another animal model for testing vif-deletion
utants as attenuated lentiviral vaccines.
MATERIALS AND METHODS
onstruction of FIV-pPPRDvif
The FIV vif mutant clone was derived from a plasmid
ncoding an infectious molecular clone of FIV-desig-
ated FIV-pPPR (Phillips et al., 1990; Sparger et al., 1994).
igestion with SauI and HindIII restriction enzymes fol-
owed by generation of blunt ends with Klenow fragment
as used to create a 375-bp deletion (bases 5330–5704)
ithin the vif gene of WT FIV-pPPR (Phillips et al., 1990).
ideoxynucleotide sequencing confirmed the presence
f the 375-bp vif deletion in the FIV-pPPRDvif construct
Fig. 1). Plasmid DNA stocks were prepared by standard
FIG. 5. Replication kinetics of FIV-pPPRDvif-infected PBMCs. Con-
anavalin A-stimulated PBMCs (4 3 106) were infected with WT FIV-
PPR or FIV-pPPRDvif at 6.8 ng of virion-associated FIV p24gag or
ock infected. Inocula were removed 24 h p.i., and cell culture super-
atants were assayed every 3–5 days. Virus production was measured
os in Fig. 2.lkaline lysis and centrifugation to equilibrium twice in
esium chloride-ethidium bromide gradients (Sambrook
t al., 1989).
mmunoprecipitation
CrFK cells (American Type Culture Collection CCL 94)
ere transfected with either WT FIV-pPPR or FIV-
PPRDvif by electroporation and cultivated as previously
escribed (Shacklett and Luciw, 1994) using 10 mg of
lasmid DNA/3 3 106 cells. By 48 h post-transfection,
ell extracts were prepared from transfected cells (107
ells), as well as uninfected CrFK cells (negative control),
nd a feline lymphoid cell line chronically infected with
etaluma FIV (FL4 cells) (positive control) (Yamamoto et
l., 1991). Viral proteins were immunoprecipitated from
ell extracts with FIV-infected cat sera using protocols
reviously described (Sawai et al., 1996). Immunoprecipi-
ates were analyzed for FIV p24gag expression by SDS–
AGE and Western blot analysis using a mouse mono-
lonal antibody specific for FIV p24gag (provided by N. C.
edersen, University of California at Davis), as previously
escribed (Sawai et al., 1996). Briefly, after SDS–PAGE,
roteins were transferred to a PVDF membrane that was
robed using FIV p24gag-specific monoclonal antibody,
nd p24gag was detected using an alkaline phos-
hatase-conjugated rabbit anti-mouse antibody.
mmunocytochemistry
CrFK cells (1 3 105) transfected with either WT FIV-
PPR or FIV-pPPRDvif as described above were seeded
FIG. 6. Replication kinetics of FIV-pPPRDvif-infected MDMs. MDMs
ere infected with WT FIV-pPPR or FIV-pPPRDvif at 68 ng of virion-
ssociated FIV p24gag or mock infected. Inocula were removed 24 h
.i., and cell culture supernatants were assayed every 3–5 days. Virus
roduction was measured by a commercial p24gag antigen capture
LISA (IDEXX Corporation, Portland, ME).nto Thermanox tissue culture slides (Nunc Inc., Naper-
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29FIV vif GENEille, IL) from 24 to 48 h post-transfection. Uninfected
rFK cells seeded onto Thermanox tissue culture slides
erved as a negative control. Slides were fixed and
tained for immunocytochemical analysis (Vectastain
BC kit; Vector Laboratories, Burlingame, CA) using a
ouse monoclonal antibody specific for FIV gp100env
provided by C. Grant, Custom Monoclonals, West Sac-
amento, CA) and biotinylated horse anti-mouse IgG
Vector Laboratories) as the secondary antibody under
onditions recommended by the manufacturer. Color
as developed using ABC/HRP reagent and AEC sub-
trate (Vector Laboratories).
ransfection and cocultivation
CrFK cells were transfected by electroporation, as
escribed above. At 24 h post-transfection, CrFK cells
ere cocultivated with either 1.5 3 107 PBMCs or 1 3 107
-258 cells in RPMI 1640 medium with 10% heat-
nactivated FCS, 100 IU of penicillin and 100 mg of strep-
omycin/ml, 100 U of recombinant IL-2/ml, 50 mM 2-mer-
aptoethanol (2-ME), and 10 mM HEPES; at 24 h after
ocultivation, nonadherent cells were harvested and
ropagated for up to 21 days. Cell culture supernatants
ere collected every 3–5 days, and virus production was
easured by an FIV p24gag antigen capture ELISA (Dan-
ekar et al., 1992).
nfection of PBMCs
WT FIV-pPPR and FIV-pPPRDvif virus stocks were gen-
rated as previously described (Sparger et al., 1997),
xcept the FIV-pPPRDvif virus stock was prepared by
hort-term passage on K-258 cells. The previously de-
cribed pSV-pPPR proviral construct was used to gener-
te the WT FIV-pPPR virus stock (Sparger et al., 1997).
nfection studies were conducted using equal concen-
rations of virion-associated p24gag, as determined by
IV p24gag antigen capture ELISA. Concanavalin A-stim-
lated feline specific pathogen-free (SPF) PBMCs (5 3
06), isolated and cultivated as previously described
Sparger et al., 1994), were plated in duplicate wells of
-well plates and inoculated with 6.8 ng of virion-
ssociated FIV p24gag, a viral antigen concentration
qual to 100 TCID50 of WT FIV-pPPR. Inocula were re-
oved 24 h p.i., and cell culture supernatants were
ssayed for FIV p24gag by ELISA every 3–5 days for up
o 18 days.
nfection of MDMs
MDM cultures were prepared by plating 107 freshly
solated PBMCs in RPMI 1640 medium supplemented
ith 10% pooled, heat-inactivated SPF cat serum and
0% heat-inactivated FCS in duplicate wells of a 24-well
late. Nonadherent cells were gently washed away with
anks’ balanced salt solution 48–72 h after plating. Ad-
erent cells were cultured 7–10 days until confluentonolayers were formed and fed fresh media every 3–4
ays. WT FIV-pPPR or FIV-pPPRDvif virus preparations
ontaining 68 ng of p24gag, a concentration equal to 103
CID50 of WT FIV-pPPR, were used to infect duplicate
ells of MDMs. Inocula were removed 24 h p.i., and viral
eplication was monitored for FIV p24gag by a commer-
ial ELISA (IDEXX Corporation, Portland, ME) every 3–4
ays up to 14 days p.i.
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